Suk-Hyung Kwon
Chief Executive Officer en NOVAREX CO.,LTD. .
Fortuna: 24 M $ al 31/03/2024
Perfil
Suk-Hyung Kwon is currently the Chairman & Chief Executive Officer at NOVAREX Co., Ltd.
since 2019.
He is also the Chief Executive Officer at NOVAKMED since 2017 and the Chairman of the Korea Health Supplements Association since 2016.
Additionally, Dr. Kwon is a Senior Associate at STIC Investments, Inc. (South Korea).
Previously, he worked as a Director at Rexahn Pharmaceuticals, Inc. from 2001 to 2005.
Dr. Kwon holds a doctorate degree from Chung-Ang University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NOVAREX CO., LTD.
17.83% | 15/11/2023 | 3 344 214 ( 17.83% ) | 24 M $ | 31/03/2024 |
Cargos activos de Suk-Hyung Kwon
| Empresas | Cargo | Inicio |
|---|---|---|
| NOVAREX CO.,LTD. | Chief Executive Officer | 22/03/2019 |
| NOVAKMED | Chief Executive Officer | 02/01/2017 |
| Korea Health Supplements Association | Chairman | 25/02/2016 |
STIC Investments, Inc. (South Korea)
 STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Private Equity Analyst | - |
Antiguos cargos conocidos de Suk-Hyung Kwon.
| Empresas | Cargo | Fin |
|---|---|---|
| REXAHN PHARMACEUTICALS, INC. | Director/Board Member | 14/06/2005 |
Formación de Suk-Hyung Kwon.
| Chung-Ang University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| NOVAREX CO.,LTD. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
STIC Investments, Inc. (South Korea)
STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Finance |
| Korea Health Supplements Association | |
| NOVAKMED |
- Bolsa de valores
- Insiders
- Suk-Hyung Kwon
